GenomOncology has entered a strategic partnership with the Glioblastoma Foundation to enhance genomic testing for glioblastoma, the most aggressive type of brain cancer. This collaboration integrates GenomOncology’s advanced Pathology Workbench (PWB) platform into the Foundation’s new genomic testing lab, helping patients gain faster access to crucial genetic insights that can guide precision treatment.
Health Technology Insights: Jopari Solutions Appoints John Gilmartin as President
Glioblastoma is one of the most challenging cancers to treat, with an average survival of just over a year. Nearly all patients show some form of genomic variation, and more than half have copy number alterations. These genetic findings are key to shaping better diagnoses and identifying potential therapeutic targets, giving patients a chance at improved outcomes.
The partnership highlights the speed and capability of GenomOncology’s PWB software, which simplifies complex genomic data from multiple testing sources into clear, actionable clinical reports. Impressively, the Glioblastoma Foundation’s lab began producing reports just two weeks after signing the agreement, demonstrating the efficiency of the system in supporting rapid, data-driven care for critically ill patients.
Health Technology Insights: Aceso and Samsung Partner to Enhance Patient Engagement
Patient testing includes comprehensive DNA and RNA sequencing, RNA fusion panel analysis, and whole genome sequencing methylation testing for MGMT. GenomOncology’s platform consolidates these results into detailed, tiered reports that interpret genetic variants, identify treatment options, and match patients to relevant clinical trials. According to Brad Wertz, CEO of GenomOncology, this collaboration represents a step forward in precision oncology. He explained that the goal is to create unified clinical genomic reports that guide physicians toward the best treatment paths for each patient, accelerating the adoption of advanced care models through the Foundation’s research efforts.
A key feature of the platform is its ability to analyze MGMT methylation data, a crucial biomarker that helps predict resistance to the chemotherapy drug temozolomide. This testing capability enables clinicians to personalize care plans and is offered by only a limited number of labs in the U.S. Dr. Gita Kwatra, CEO of the Glioblastoma Foundation, praised the partnership, noting that GenomOncology’s team delivered a fully operational platform and comprehensive training within two weeks. She emphasized that this technology will allow the Foundation to process complex genomic data more efficiently, providing oncologists with the information they need to recommend individualized treatments and accelerate brain cancer research.
Health Technology Insights: Incyte Expands Moments of Clarity Program
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
